gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · RYTMHealthcarePharmaceuticals

Rhythm Pharmaceuticals, Inc. Common Stock (RYTM)

$110.68+28.04%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$110.68▲ 5.42% in range
Nov 4, 2025Low $75.82 · High $117.62Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Rhythm Pharmaceuticals closed at $110.68 on Nov 4, up 28.04%, 5.9% below its 52-week closing high. Volume of 5.5M shares was 5.37× its 20-day average (well above normal).

Split-adjusted performance: +21.9% over one month, +14.6% over six months, -2.7% over one year.

In the quarter ended Jun 30, 2026, revenue was $71.25M, up 46.9% from a year earlier, with a net margin of -70.7%.

Short interest was 11.0M shares at the Oct 15 settlement, up 2.2% from the prior report (17.1% of float, 13.5 days to cover).

Market cap$7.62B68.9M shares
Revenue · quarter$71.3M+46.9% YoY
Diluted EPS$-0.73—
P/E · TTM—P/S 31.8×
Net margin-70.7%Gross 87.5%
Dividend yieldNone
52-week range75.82 – 117.62−5.9% from high
Volume5.5M5.37× 20-day avg
Volatility · 60d61.5%Annualised
Short % of float17.1%13.5 days to cover
Net cash$224.8MCash $330.9M
Next earnings—Not scheduled
Split-adjusted performance
1W +20.3%1M +21.9%3M −1.3%6M +14.6%YTD +3.4%1Y −2.7%3Y +386.1%5Y +863.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum79
Revenue growth78
Net margin44
Value (low P/E)—
Size93

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short11.0M+2.2% vs prior
Days to cover13.5Settled Oct 15
% of float17.1%
Short vol. 10d61.1%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
RYTMRhythm Pharmaceuticals$110.68+28.04%+14.6%+46.9%−70.7%—$7.62B
KNSAKiniksa Pharmaceuticals International$96.12+3.03%+65.1%+58.1%16.6%68.9$7.55BCompare
ALKSAlkermes$45.89+0.44%+29.9%+21.8%3.4%—$7.70BCompare
PRAXPraxis Precision Medicines$284.79+1.53%−15.8%———$7.95BCompare
AXSMAxsome Therapeutics$137.00−1.87%−38.5%+51.9%−5.0%—$7.18BCompare
AMRXAmneal Pharmaceuticals$19.95−1.29%+46.5%+9.9%7.2%44.2$6.95BCompare
CORTCorcept Therapeutics$79.22−3.31%+51.9%+31.7%16.8%157.2$8.56BCompare
ORKAOruka Therapeutics$101.41+1.87%+45.3%———$6.71BCompare
IONSIonis Pharmaceuticals$40.15−0.67%−47.8%−40.7%−42.8%—$6.67BCompare

News about Rhythm Pharmaceuticals

All news →
Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl SyndromeGlobeNewswire Inc. · 17h ago▲ PositiveRhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue EstimatesZacks Investment Research · 1d agoNeutralRhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License AgreementGlobeNewswire Inc. · 2d ago▲ PositiveRhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research · Oct 27, 2026▲ PositiveRhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic ObesityGlobeNewswire Inc. · Oct 13, 2026▲ Positive

Quick answers

What does Rhythm Pharmaceuticals do?
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases.
What is RYTM's market cap?
$7.62B, based on the Nov 4 close of $110.68.
Does Rhythm Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of RYTM is sold short?
11.0M shares, 17.1% of float, as of Oct 15, 2026.
What sector is RYTM in?
Healthcare, in the Pharmaceuticals industry.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

HQ: Boston, MA414 employeesListed Oct 5, 2017rhythmtx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology